MPN PACES

  • Research type

    Research Study

  • Full title

    The Myeloproliferative neoplasm (MPN) Physical ACtivity Engagement Study (PACES): A feasibility study of a pedometer based physical activity intervention for patients with Myeloproliferative neoplasms

  • IRAS ID

    251695

  • Contact name

    Charlene M. McShane

  • Contact email

    c.mcshane@qub.ac.uk

  • Sponsor organisation

    Queens University Belfast

  • Duration of Study in the UK

    1 years, 11 months, 31 days

  • Research summary

    Myeloproliferative neoplasms (MPNs), a group of rare blood cancers, often lead to a reduced overall quality of life (QoL) and capacity to complete routine daily activities. Medical treatments can improve symptom and QoL, however, MPN patients have a significantly higher burden of fatigue than the general population. Non-medical treatment such as physical activity (PA) may be an effective approach to enable MPN patients to manage symptoms and improve QoL alongside standard therapy. The primary aim of this research is to identify an appropriate methodology to undertake a fully powered RCT within the UK Clinical Trials Network recruiting patients from up to 12 sites in the UK.
    Sixty patients with MPN from the Belfast Health and Social Care Trust will be recruited into the feasibility study and randomised to one of three groups (20 patients in each group). One group (Group A) will serve as a standard care control group. One intervention group (Group B) will be provided with a pedometer (device that measures the number of steps someone takes), advice on how to use the device and PA behaviour change information (Macmillan 'Move More' guide) by a trained research nurse. The final intervention group (Group C) will receive a pedometer, information and advice on PA behaviour change (Macmillan 'Move More' guide) by a trained research nurse with motivational telephone discussions weekly in month 1, fortnightly in month 2 and once in month 3. Questionnaires measuring PA, self-efficacy, fatigue, other symptoms and QoL, will be administered at baseline, 12 weeks and 24 weeks. Patient experiences’ of their involvement in the research will be assessed using semi-structured interviews by researchers from Queen’s University Belfast. The aim of this research is to identify an appropriate methodology to undertake a fully powered RCT within the UK Clinical Trials Network recruiting patients from up to 12 sites in the UK.

  • REC name

    West of Scotland REC 4

  • REC reference

    19/WS/0139

  • Date of REC Opinion

    24 Oct 2019

  • REC opinion

    Further Information Favourable Opinion